Kazakhstan vs Malaysia: Average cost of drugs for extensively drug-resistant tuberculosis
Kazakhstan
6,329 constant 2022 US$
in 2023
Malaysia
10,000 constant 2022 US$
in 2024
Kazakhstan rank
5th
Malaysia rank
4th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kazakhstan
- Malaysia
How they compare
Malaysia currently reports 10,000 constant 2022 US$ against 6,329 constant 2022 US$ in Kazakhstan, a difference of 3,671 constant 2022 US$.
That makes Malaysia's figure about 1.6 times Kazakhstan's.
Across all 7 years both countries report, Malaysia has been ahead every year.
Kazakhstan ranks 5th and Malaysia ranks 4th of 56 countries.
Malaysia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,871 constant 2022 US$ | 45,000 constant 2022 US$ | 41,129 constant 2022 US$ | Malaysia |
| 2020s | 4,806 constant 2022 US$ | 25,000 constant 2022 US$ | 20,194 constant 2022 US$ | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kazakhstan or Malaysia?
- Malaysia, at 10,000 constant 2022 US$ against 6,329 constant 2022 US$ in Kazakhstan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kazakhstan and Malaysia?
- 3,671 constant 2022 US$, with Malaysia ahead.
- How many years of comparable data are there for Kazakhstan and Malaysia?
- 7 years are reported by both, from 2017 to 2023.
- How do Kazakhstan and Malaysia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kazakhstan ranks 5th and Malaysia ranks 4th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.